Publisher Correction: MLIP genotype as a predictor of pharmacological response in primary open-angle glaucoma and ocular hypertension
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
Guardado en:
Autores principales: | María I. Canut, Olaya Villa, Bachar Kudsieh, Heidi Mattlin, Isabel Banchs, Juan R. González, Lluís Armengol, Ricardo P. Casaroli‑Marano |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/b8c420de0a704146a03977528df10e64 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Brinzolamide ophthalmic suspension: a review of its pharmacology and use in the treatment of open angle glaucoma and ocular hypertension
por: Michele Iester
Publicado: (2008) -
Differential pharmacology and clinical utility of preservative-free tafluprost in the treatment of ocular hypertension and glaucoma
por: Ermiş SS
Publicado: (2012) -
Blood pressure, ocular perfusion pressure and open-angle glaucoma in patients with systemic hypertension
por: Cantor E, et al.
Publicado: (2018) -
Safety and tolerability of tafluprost in treatment of elevated intraocular pressure in open-angle glaucoma and ocular hypertension
por: Dorota Pozarowska
Publicado: (2010) -
Efficacy and safety of travoprost/timolol vs dorzolamide/timolol in patients with open-angle glaucoma or ocular hypertension
por: Miguel A Teus, et al.
Publicado: (2009)